Insights
Perspectives on portfolio strategy, execution discipline, and lifecycle management from the Tarseva team.
Portfolio strategy
Organizations invest heavily in portfolio reviews, only to find that the decisions made in the room don't survive contact with the organization. The problem is rarely analytical. It's structural.
Every week a go/no-go decision is delayed, resources are consumed, options narrow, and the cost of being wrong increases. Understanding the true cost of indecision is the first step to building a culture that decides.
The difference between a PMO that drives outcomes and one that produces reports is not headcount or technology. It is the degree to which governance is connected to decision-making authority.
Loss of exclusivity is one of the most foreseeable events in pharmaceutical development. Yet organizations consistently underinvest in lifecycle strategy until the window for meaningful action has narrowed significantly.
Investors have become more sophisticated about pipeline risk. The organizations that earn their confidence are those that can articulate not just what they're developing, but why those programs are the right ones to be developing now.
Most repurposing efforts are opportunistic — triggered by a failed indication or an unexpected signal. Organizations that treat repurposing as a systematic capability, not a fallback, consistently extract more value from their existing asset base.
The EU Medical Device Regulation has been in force long enough to generate meaningful data about which organizations were genuinely prepared and which were not. The patterns are instructive.
Tarseva publishes thinking on the decisions that matter most in life sciences. New articles are added regularly.
